文献速递其他结缔组织病血管炎

系统性硬化症相关肺动脉高压初始治疗策略与结局:EUSTAR分析

Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis-associated pulmonary arterial hypertension: a EUSTAR analysis.
PubMed 文献 · Arthritis Rheumatol · 2026-10-15

该研究基于EUSTAR队列(2000-2021)分析301例初治系统性硬化症相关肺动脉高压(SSc-PAH)患者,描述不同血流动力学阈值和风险分层下的初始治疗策略及结局关联。结果显示持续初始治疗与较低死亡和PAH进展风险相关,但ITT与AT分析结果不一致,提示观察性比较的挑战。

要点

  • 持续初始治疗与较低死亡风险相关(单药HR 0.50,联合HR 0.40)。
  • 持续初始治疗与较低PAH进展风险相关(HR 0.37)。
  • 轻血流动力学亚组死亡估计方向一致但不精确。

核心结论

  • 初始治疗策略反映血流动力学严重程度和基线风险,但存在实施差异。
  • 持续初始治疗与较低死亡和PAH进展风险相关。
  • ITT与AT估计的对比凸显观察性治疗-结局比较的挑战。

研究设计与样本

  • 基于EUSTAR队列(2000-2021)的观察性分析,纳入301例符合2022年血流动力学定义的初治SSc-PAH患者。
  • 初始治疗定义为右心导管检查后4个月内启动的治疗,主要采用As-treated(AT)分析,意向性治疗(ITT)分析为支持性。

主要发现

  • 301例患者中198例(66%)启动治疗,170例维持治疗≥3个月。
  • 轻血流动力学损害亚组(mPAP 21-24 mmHg和/或PVR 2-3 WU)中31%启动治疗,而符合旧血流动力学定义者中79%启动治疗。
  • 联合治疗比例从低危到高危分层由14%增至67%。
  • 中位随访3.9年,125例(42%)死亡,85/227例(37%)出现PAH进展。
  • 调整后ITT分析显示治疗与结局无关联;调整后AT分析显示持续单药治疗(HR 0.50,95%CI 0.27-0.92)和联合治疗(HR 0.40,95%CI 0.18-0.88)与较低死亡风险相关,持续初始治疗与较低PAH进展风险相关(HR 0.37,95%CI 0.18-0.76)。

关键数值与推荐

  • 采用2022年血流动力学定义:mPAP 21-24 mmHg和/或PVR 2-3 WU为轻血流动力学损害亚组。
  • 初始治疗为右心导管检查后4个月内启动的治疗。
  • 结局包括全因死亡和36个月PAH进展。

临床怎么用

  • 临床中应认识到SSc-PAH初始治疗策略存在基于血流动力学和风险的差异。
  • 持续初始治疗可能与改善结局相关,但需结合观察性研究局限性解读。
  • 轻血流动力学损害患者中治疗启动率较低,需个体化评估。

局限性

  • 观察性研究设计,ITT与AT分析结果不一致提示存在混杂可能。
  • 轻血流动力学亚组死亡估计不精确。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Real-world initial treatment strategies in SSc-PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. METHODS: We analysed treatment-naïve SSc-PAH patients in EUSTAR (2000-2021) fulfilling the 2022 haemodynamic definition. Initial therapy comprised treatment initiated within 4 months of RHC. As-treated (AT) analyses were primary and intention-to-treat (ITT) analyses supportive. Outcomes were all-cause mortality and 36-month PAH progression. RESULTS: Among 301 patients, 198 (66%) initiated therapy and 170 maintained therapy for ≥3 months. Therapy was initiated in 31% with milder haemodynamic impairment (mPAP 21-24 mmHg and/or PVR 2-3 WU) versus 79% fulfilling the previous haemodynamic definition; combination therapy increased from 14% to 67% across low- to high-risk strata. Over a median 3.9 years, 125 (42%) died and 85/227 (37%) progressed. Adjusted ITT analyses showed no association with either outcome, whereas adjusted AT analyses showed lower mortality risk with sustained monotherapy and combination therapy (HR 0.50, 95% CI 0.27-0.92 and HR 0.40, 95% CI 0.18-0.88, respectively) and lower PAH progression risk with sustained initial therapy (HR 0.37, 95% CI 0.18-0.76). In the milder haemodynamic subgroup, the mortality estimate was directionally consistent but imprecise. CONCLUSION: Initial treatment strategies reflected haemodynamic severity and baseline risk, while variation suggested potential implementation gaps. Sustained initial therapy was associated with lower risks of mortality and PAH progression. Contrasting ITT and AT estimates highlight challenges in observational treatment-outcome comparisons. Findings in the milder haemodynamic subgroup support dedicated prospective studies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bjørkekjær HJ, Bruni C, Broch K, et al. Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis-associated pulmonary arterial hypertension: a EUSTAR analysis. Arthritis Rheumatol. 2026. PMID: 42876376. doi:10.1002/art.70372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。